---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-133331"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:14:11.465574+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated

## Summary
- Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
- Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.
- All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.
- Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.
- Audit of 2025 financials not completed; company will not file 10-K or any periodic reports.

## SEC filing metadata
- accession: 0001193125-26-133331
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- confidence: high
- sec_items: 1.03, 2.04, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/0001193125-26-133331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/d87973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-133331
- JSON: https://secwatch.observer/filing/0001193125-26-133331.json
- Plain text: https://secwatch.observer/filing/0001193125-26-133331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.